Ascentage Pharma Group International (ASPHF)

Ascentage Pharma Group International (ASPHF) Healthcare & Pipeline Overview

Ascentage Pharma Group International is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. The company leverages a broad pipeline of small molecule inhibitors, including HQP1351 for CML and APG-2575 for hematologic malignancies, targeting unmet medical needs in significant therapeutic areas across the US and Mainland China.

What Is the Investment Thesis for ASPHF?

Ascentage Pharma Group International presents as a clinical-stage biotechnology entity with a diverse pipeline targeting high-value therapeutic areas such as oncology and chronic HBV. The company's lead asset, HQP1351, a BCR-ABL inhibitor, addresses a specific unmet need in CML patients with T315I mutation and TKI resistance, representing a significant market opportunity upon potential approval. Further value drivers include APG-2575, a Bcl-2 selective inhibitor in Phase Ib/II, and APG-115, an MDM2-p53 inhibitor, both with broad potential in hematologic and solid tumors. Strategic collaborations with industry leaders like Pfizer and Innovent Biologics validate its scientific approach and provide potential pathways for accelerated development and commercialization. However, as a clinical-stage company, Ascentage Pharma currently operates at a significant loss, evidenced by a -216.7% profit margin, reflecting substantial R&D expenditures. The investment thesis hinges on successful clinical trial outcomes, regulatory approvals, and eventual commercialization or licensing agreements for its pipeline assets, which would transition the company from a development-focused entity to one with revenue-generating products.

Based on FMP financials and quantitative analysis

ASPHF Key Highlights

• Ascentage Pharma Group International maintains a gross margin of 84.1%, indicating strong pricing power or efficient cost of goods sold for any revenue generated, typical for biotech companies with early-stage licensing or collaboration income.
• The company operates with a profit margin of -216.7%, reflecting its status as a clinical-stage biotechnology firm with substantial ongoing research and development expenses and limited commercial revenue.
• With a market capitalization of $1.69B, Ascentage Pharma is positioned as a mid-cap biotechnology company, suggesting investor confidence in its pipeline potential despite current unprofitability.
• The company employs 567 individuals, indicating a significant investment in its scientific, clinical, and operational teams to support its extensive drug development pipeline.
• Ascentage Pharma's stock exhibits a Beta of 0.72, suggesting lower volatility compared to the broader market, which might appeal to investors seeking less market-sensitive exposure within the biotechnology sector.

Who Are ASPHF's Competitors?

ASPHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ASPHF's Key Strengths?

• Diverse and advanced clinical pipeline targeting high-value therapeutic areas like oncology and chronic HBV.
• Strategic collaborations with major pharmaceutical companies (e.g., Pfizer, Innovent Biologics) validating its scientific approach.
• Specialization in small molecule inhibitors addressing specific, challenging mutations and pathways (e.g., T315I mutation in CML).
• Strong gross margin of 84.1% indicating potential for profitability upon commercialization.

What Are ASPHF's Weaknesses?

• Significant negative profit margin (-216.7%) due to substantial R&D expenditures as a clinical-stage company.
• Reliance on successful clinical trial outcomes and regulatory approvals, which are inherently uncertain and lengthy processes.
• Limited current revenue streams, making the company highly dependent on future product commercialization or licensing deals.
• Operations in both the US and Mainland China may introduce complexities related to differing regulatory environments and market dynamics.

What Could Drive ASPHF Stock Higher?

• Positive clinical trial results for HQP1351 in TKI-resistant CML patients, potentially leading to regulatory submissions and approvals in key markets.
• Advancement of APG-2575 from Phase Ib/II to later-stage clinical trials for hematologic malignancies and solid tumors, signaling progress in its development.
• New or expanded collaboration agreements with major pharmaceutical partners, potentially providing additional funding, expertise, or market access for pipeline assets.
• Continued progression of other pipeline candidates like APG-115, APG-1387, and UBX1967/1325 through their respective clinical stages, demonstrating R&D productivity.
• Regulatory milestones, such as Fast Track designations or Breakthrough Therapy designations, which could accelerate the review and approval process for promising drug candidates.

What Are the Key Risks for ASPHF?

• Financial-distress signal — its Altman Z-Score of -0.00 sits in the distress zone (elevated bankruptcy risk).
• Failure of key clinical trials for lead drug candidates like HQP1351 or APG-2575, which would significantly impact the company's valuation and future prospects.
• High cash burn rate and negative profit margin (-216.7%) inherent to a clinical-stage biotechnology company, necessitating future financing that could dilute existing shareholders.
• Intense competition from larger, more established pharmaceutical companies with greater resources and potentially more advanced therapies in oncology and HBV.
• Regulatory setbacks or delays in obtaining approvals from health authorities in the United States or Mainland China, prolonging time to market and increasing development costs.
• Risks associated with trading on the OTC 'Other' tier, including lower liquidity, reduced transparency, and potential difficulties in accessing timely financial information.

What Are the Growth Opportunities for ASPHF?

• **Advancement of HQP1351 for CML Treatment:** HQP1351, Ascentage Pharma's primary product, is a BCR-ABL inhibitor specifically designed to target challenging BCR-ABL mutants, including those with the T315I mutation, and patients with tyrosine kinase inhibitor (TKI) resistant chronic phase chronic myeloid leukemia (CML). The global market for CML treatments is substantial, with a significant segment dedicated to patients who have failed prior TKI therapies, representing a critical unmet medical need. Successful progression through clinical trials and regulatory approval for HQP1351 would unlock access to this specialized patient population, potentially generating significant revenue streams. The timeline for this opportunity is contingent on ongoing clinical trial results and regulatory review processes, likely spanning several years until full commercialization.
• **Expansion of APG-2575 into Hematologic Malignancies and Solid Tumors:** APG-2575, an orally administered Bcl-2 selective inhibitor, is currently under Phase Ib/II clinical study for both hematologic malignancies and solid tumors. The Bcl-2 pathway is a well-validated target in oncology, with existing approved drugs demonstrating its therapeutic potential. The global market for hematologic malignancies alone is projected to reach tens of billions of dollars, while solid tumors represent an even larger market. Expanding the indications for APG-2575, particularly into multiple tumor types, could significantly broaden its commercial potential. This opportunity's realization depends on favorable safety and efficacy data from ongoing and future clinical trials, with a potential market entry timeline in the mid-to-late 2020s.
• **Development of APG-115 for MDM2-p53 Pathway Inhibition:** APG-115 is an oral small molecule inhibitor targeting the MDM2-p53 protein-protein interaction, a crucial pathway in cancer biology. The p53 tumor suppressor gene is frequently mutated or inactivated in a wide range of human cancers, making its restoration a highly attractive therapeutic strategy. This drug candidate is being developed for treating solid tumors and hematological malignancies. The market for p53 pathway modulators is an emerging area with high potential, given the broad applicability across various cancer types. Successful clinical development and regulatory approval of APG-115 could position Ascentage Pharma as a leader in this innovative therapeutic space, with market opportunities potentially materializing in the late 2020s or early 2030s.
• **Therapeutic Potential of APG-1387 for HBV and Advanced Solid Tumors:** APG-1387 is a small molecule inhibitor of apoptosis proteins, targeting both advanced solid tumors and chronic hepatitis B virus (HBV) infection. Chronic HBV infection affects hundreds of millions globally, with a significant unmet need for curative or highly effective therapies. The dual indication for APG-1387 provides two distinct, large market opportunities. The global market for HBV therapeutics is substantial, while the market for advanced solid tumors is vast and continuously growing. Demonstrating efficacy in either or both indications would provide significant growth impetus. The timeline for these opportunities is dependent on successful clinical trial completion and regulatory submissions, likely extending into the late 2020s.
• **Strategic Collaborations with Global Pharmaceutical Leaders:** Ascentage Pharma has established collaboration relationships with major biotechnology and pharmaceutical companies, including Innovent Biologics, Inc., National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. These partnerships are crucial growth drivers, providing access to additional R&D expertise, funding, broader geographic reach, and potential co-development or licensing agreements. For instance, a successful partnership with Pfizer could significantly accelerate the development and commercialization of a pipeline asset, leveraging Pfizer's global infrastructure. These collaborations can de-risk development programs and provide non-dilutive funding, accelerating the path to market for Ascentage's innovative therapies. The ongoing nature of these collaborations provides continuous opportunities for joint development and commercialization.

What Opportunities Does ASPHF Have?

• Potential market entry for HQP1351 in TKI-resistant CML, addressing a critical unmet medical need with a specialized patient population.
• Expansion of pipeline assets like APG-2575 and APG-115 into multiple hematologic and solid tumor indications, broadening market reach.
• Leveraging existing collaborations to accelerate drug development, gain market access, and secure non-dilutive funding.
• Exploration of new indications or therapeutic areas for existing pipeline drugs, such as APG-1387 for both HBV and solid tumors.

What Threats Does ASPHF Face?

• High risk of clinical trial failures, which can lead to significant financial losses and delays in product development.
• Intense competition from larger pharmaceutical companies and other biotechnology firms with similar or more advanced therapies.
• Regulatory hurdles and potential delays in obtaining approvals from health authorities in both the US and China.
• Patent expirations or challenges to intellectual property, potentially impacting future market exclusivity and profitability.
• Capital intensity of drug development, requiring ongoing financing that could dilute existing shareholders if not managed effectively.

What Are ASPHF's Competitive Advantages?

• Proprietary pipeline of novel small molecule inhibitors targeting critical disease pathways, such as BCR-ABL, Bcl-2, and MDM2-p53.
• Expertise in developing drugs for specific, challenging mutations like T315I in CML, addressing significant unmet medical needs.
• Strategic collaborations with established pharmaceutical companies (e.g., Pfizer, Innovent Biologics) that validate its scientific approach and provide development resources.
• Intellectual property protection (patents) surrounding its drug candidates and therapeutic approaches, providing market exclusivity upon approval.
• Clinical-stage progress of multiple assets, indicating a significant investment in R&D and advancement beyond early discovery phases.

What Does ASPHF Do?

Ascentage Pharma Group International, founded in 2009 and headquartered in Suzhou, China, is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapies. The company's strategic focus lies in addressing critical unmet medical needs within oncology, chronic hepatitis B virus (HBV) infection, and age-related diseases. Operating across both the United States and Mainland China, Ascentage Pharma has cultivated a robust and diverse pipeline of drug candidates, primarily centered on inhibitors of protein-protein interactions and other targeted mechanisms crucial for disease progression. Its flagship product, HQP1351, is a promising BCR-ABL inhibitor specifically designed to target BCR-ABL mutants, including those with the challenging T315I mutation, and is being developed for patients with tyrosine kinase inhibitor-resistant chronic phase chronic myeloid leukemia. Beyond HQP1351, the pipeline includes APG-2575, an orally administered Bcl-2 selective inhibitor currently undergoing Phase Ib/II clinical study for hematologic malignancies and solid tumors. Another key candidate is APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction, being investigated for solid tumors and hematological malignancies. Additionally, APG-1387, a small molecule inhibitor of apoptosis proteins, is under development for advanced solid tumors and chronic HBV infection. The company's commitment to innovation extends to other programs such as APG-1252, APG-2449, APG-5918 (pre-clinical), APG-265 (IND-enabling), and UBX1967/1325 (Phase II for DME). Ascentage Pharma has also strategically forged collaboration relationships with major biotechnology and pharmaceutical companies, including Innovent Biologics, Inc., Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited, as well as academic institutions like the National Cancer Institute, to accelerate its research and development efforts and expand its global reach.

What Products and Services Does ASPHF Offer?

• Develops novel small molecule therapies for various cancers, chronic hepatitis B virus (HBV), and age-related diseases.
• Focuses on a pipeline of drug candidates that are primarily small molecule inhibitors of protein-protein interactions.
• Advances HQP1351, a BCR-ABL inhibitor, for chronic myeloid leukemia (CML) patients, especially those with T315I mutation or TKI resistance.
• Conducts Phase Ib/II clinical studies for APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors.
• Investigates APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction, for solid tumors and hematological malignancies.
• Develops APG-1387, a small molecule inhibitor of apoptosis proteins, for advanced solid tumors and chronic HBV infection.
• Maintains additional pipeline assets including APG-1252, APG-2449, APG-5918 (pre-clinical), APG-265 (IND-enabling), and UBX1967/1325 (Phase II).
• Engages in strategic collaboration relationships with major pharmaceutical companies and academic institutions to support its R&D efforts.

How Does ASPHF Make Money?

• Primarily a research and development (R&D) focused biotechnology company, investing heavily in the discovery and clinical advancement of novel drug candidates.
• Generates potential future revenue through the successful commercialization of its proprietary drug candidates, either directly or through licensing agreements with larger pharmaceutical partners.
• Engages in strategic collaborations and partnerships with other pharmaceutical companies and academic institutions, which may involve upfront payments, milestone payments, and royalties on future sales.
• Operates with a long-term investment horizon, typical for clinical-stage biotech, where significant capital is expended on R&D before potential product revenues materialize.

What Industry Does ASPHF Operate In?

Ascentage Pharma Group International operates within the highly specialized and competitive biotechnology industry, a sub-sector of healthcare characterized by intensive research and development, lengthy clinical trials, and significant regulatory hurdles. The company is positioned as a clinical-stage entity, focusing on novel small molecule therapies for oncology, chronic hepatitis B, and age-related diseases. These therapeutic areas represent substantial global markets with ongoing unmet medical needs, driving continuous innovation. The oncology market, for instance, is projected to reach hundreds of billions globally, fueled by an aging population and advancements in targeted therapies. Ascentage Pharma's strategy of developing inhibitors for specific molecular targets, such as BCR-ABL and Bcl-2, aligns with the industry trend towards precision medicine. The competitive landscape includes large pharmaceutical companies with established pipelines and numerous smaller biotech firms vying for market share. Ascentage Pharma differentiates itself through its diverse pipeline and strategic collaborations, aiming to carve out niches in areas with high therapeutic demand.

Who Are ASPHF's Key Customers?

• Future patients suffering from various cancers, chronic hepatitis B, and age-related diseases that its therapies aim to treat.
• Healthcare providers (oncologists, hematologists, hepatologists) who would prescribe the company's approved drugs.
• Pharmaceutical and biotechnology companies seeking to license or acquire innovative drug candidates for their own pipelines.
• Research institutions and academic partners involved in co-development or early-stage research collaborations.

FY2026 estForward Outlook

Wall Street analysts project Ascentage Pharma Group International revenue of about $942.7M for fiscal 2026, with EPS near $-1.42. The estimate reflects 11 contributing analysts.

F-Score 4/9Financial Health

Ascentage Pharma Group International's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.00 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -31.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.5%, the inverse of the P/E and a quick read on earnings relative to price.

Ascentage Pharma Group International (ASPHF) Valuation Context

Valued at $1.69B, ASPHF is classified as a small-cap stock. Relative to its peer group, ASPHF's quantitative score of 51/100 is below the peer average of 65/100.

ASPHF Revenue & Earnings Trend

In Q4 2025, ASPHF generated $334.8M in top-line revenue, marking a sequential increase of 947.2%. The company recorded a net loss of $641.2M, with diluted EPS of $-1.75. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ASPHF averaged $-0.84 in diluted EPS.

Company Profile

Ascentage Pharma Group International operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Suzhou, CN. The company is led by CEO Dajun Yang. ASPHF has traded publicly since 2021.

ASPHF Financials

ASPHF Latest News

No recent news available for ASPHF.

ASPHF Analyst Consensus

ASPHF MoonshotScore

ASPHF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources